Cite
HARVARD Citation
Gregorc, V. et al. (2018). NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet oncology. 19 (6), pp. 799-811. [Online].